IVX

25.0%

0.3¢ invion limited

CEO Greg Collier appointed Director of POH, page-2

First 2 Last

Share
Profile

Follow
absolutely clueless

1,203 Posts.

114

14/04/15

12:23

Post #: 15083658
Share

Originally posted by katy28 ↑

Hi all,
Yesterday our CEO was appointed as one of 3 new Directors on the Board of Phosphagenics (ASX POH).
I know they sometimes spread themselves across a few Boards and must have applied for the position but believe we're paying him well and when our trial results come out would like to know that he intends to focus 100% on IVX.
Possibly he has done this because of some strategic value to both companies or maybe because he can see benefit in the other 2 Appointees knowledge - here is some background on the other two he will be rubbing shoulders with:

Mr Peter Lankau served as the Chief Executive Officer (CEO) of Endo Pharmaceuticals Inc. from 2005 to 2008 and as Chief Operating Officer from 2003 to 2005. From 2000 to 2003, he served as Senior Vice President of U.S. Business. Endo is a US based Pharmaceutical Company which has over recent years been one of the largest companies commercialising drugs in the pain industry. Endo’s product range includes Lidoderm (lidocaine), Percodan (oxycodone with asprin), Opana (oxymorphone) and Voltaren Gel (diclofenac) licensed from Novartis. In recent years Mr Lankau has served on multiple company boards including Nautilus Neuroscience Inc. which in 2013 sold the assets of that company, including its oral diclofenac product to Depomed Inc. for over $50 million.

Dr Ross Murdoch has over 25 years’ experience in the global Healthcare, Pharmaceutical and Biotech industries and has held senior and executive positions with global Pharmaceutical companies such as GlaxoSmithKline, Astra Zeneca and Shire Pharmaceuticals where he built significant specialised business divisions. He has also worked for much smaller companies such as Prana Biotechnology where he was COO. His appointment to the board was a natural transition, having commenced as CEO of Phosphagenics in January 2015.

Katy

Expand

Thanks Katie,
Interesting, however I believe POH headhunted GC because of the benefit of his experience. POH is where Invion was a couple of years ago... Director / CEO defrauded shareholders, 2 drugs ready for phase 2 trials, have money in the bank...
POH employed GC for his expertise needed when dealing with US regulators over clinical trial design IMO.

IVX Price at posting: 3.3¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

CCO

The Calmer Co’s Anthony Noble reflects on record breaking FY24

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

HLX

Helix investor makes partial takeover bid, proposing board changes

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

First 2 Last

Add IVX (ASX) to my watchlist

(20min delay)
Last 0.3¢		Change -0.001(25.0%)		Mkt cap ! $19.91M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.3¢	$11.16K	3.663M

Buyers (Bids)

No.	Vol.	Price($)
4	1718465	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	5804051	7

View Market Depth

No.	Vol.	Price($)
3	1500008	0.003
41	36800629	0.002
25	30066645	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	5804051	7
0.005	8372572	26
0.006	2459992	8
0.007	1100000	2
0.008	3905000	4

Last trade - 16.10pm 30/08/2024 (20 minute delay)

IVX (ASX) Chart

CEO Greg Collier appointed Director of POH, page-2

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

Lendlease sells off US east coast construction operations in latest global divestment push

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

The Calmer Co’s Anthony Noble reflects on record breaking FY24

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Helix investor makes partial takeover bid, proposing board changes

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

CEO Greg Collier appointed Director of POH, page-2

Top Stories

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

Lendlease sells off US east coast construction operations in latest global divestment push

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

The Calmer Co’s Anthony Noble reflects on record breaking FY24

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Helix investor makes partial takeover bid, proposing board changes

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News